Events

Angelman Community Webinar with Ultragenyx

October 8, 2026
2:00 pm
Share

Last month, Ultragenyx announced their phase 3 clinical trial for GTX-102 (ASPIRE) did not meet primary or secondary endpoints. Learn more about what that means. Register to attend and submit questions ahead of time.

Your donation Lifts Up the Angelman community.